Ares Trading S.A.
34 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
20
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Anti-retroviral treatment using growth hormone (US 11,707,508) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Medical device connection station (US 10,417,384) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Apparatus, Method, and System for Image-Based Human Embryo Cell Classification (US 9,177,192) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 3 fees due Jun 17 to 30, 2027 · next Jun 17
- 1 fee due Jul 7, 2027The maintenance fee for Method of reducing serine for asparagine misincorporation (US 10,526,631) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Freeze-dried formulations of FGF-18 (US 9,326,944) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,741,455 | Method for Purifying FSH In force · High confidence | In force | High confidence | |
| US 8,093,052 | Serum-free culture medium for the production of recombinant gonadotropins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,309,069 | Human serum albumin-free stabilized interferon liquid formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 8,998,842 | Injection Device With A Capacitive Proximity Sensor In force · Low confidence | In force | Low confidence | |
| US 7,866,203 | Method for the Quantitative Determination of Poloxamers In force · High confidence | In force | High confidence | |
| US 8,207,115 | Treatment of cartilage disorders with FGF-18 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,217,152 | Process for the Purification of IL-18 Binding Protein In force · High confidence | In force | High confidence | |
| US 7,846,427 | Stabilized interferon liquid formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 8,043,254 | Medication delivery device In force · From the USPTO record | In force | From the USPTO record | |
| US 8,088,096 | Injection device with a capacitive proximity sensor In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 61: 34 patents in force now held by others · 52 lapsed for an unpaid fee · 34 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
12 pending · 14 abandoned · 46 no status recorded